According to our (Global Info Research) latest study, the global Glycyrrhizic Acid Preparation market size was valued at US$ 960 million in 2025 and is forecast to a readjusted size of US$ 1513 million by 2032 with a CAGR of 6.6% during review period.
Glycyrrhizic Acid Preparations refer to drugs containing glycyrrhizic acid and its derivatives as active ingredients. Through mechanisms including anti-inflammation, antioxidation, hepatocyte membrane stabilization, and corticosteroid-like effects, they reduce serum transaminase levels and improve liver function. Unlike general hepatoprotective drugs, glycyrrhizic acid preparations have a defined anti-inflammatory and enzyme-lowering target with rapid onset (typically reducing ALT/AST within 2-4 weeks). Main products include compound glycyrrhizic acid (Minophagen), diammonium glycyrrhizinate (Chia Tai Tianqing), magnesium isoglycyrrhizinate (Chia Tai Tianqing), and monoammonium glycyrrhizinate.
Glycyrrhizic acid preparations are the “cornerstone” class of hepatoprotective and enzyme‑lowering drugs, combining rapid action with anti‑inflammatory mechanisms. Unlike chemical enzyme reducers (bifendate, bicyclol) that merely suppress ALT/AST release, glycyrrhizic acid directly inhibits liver inflammation via a corticosteroid‑like effect, while stabilizing hepatocyte membranes and scavenging free radicals – achieving ALT/AST reduction alongside improved liver histology, with significantly lower rebound rates after withdrawal. Pricing: imported originator compound glycyrrhizic acid (Stronger Neo-Minophagen C) costs RMB 15-20/day, domestic generics RMB 5-10/day; Chia Tai Tianqing’s originator magnesium isoglycyrrhizinate (Tianqing Ganmei®), an exclusive IV formulation, costs RMB 80-120/day (but patient co‑pay is low after insurance coverage); diammonium glycyrrhizinate (Ganlixin/Tianqing Ganping) costs RMB 3-8/day, one of the most economical outpatient choices. Margins diverge sharply: raw material producers (Fanzhi, MAFCO, Norevo) 20-30%; generic formulators (Kaiyin, Lepu, Yuandong) 30-40%; originator innovative products (Tianqing’s magnesium isoglycyrrhizinate) 70-80%, contributing the majority of Chia Tai Tianqing’s hepatology profits. Downstream primary applications: chronic hepatitis maintenance ~50% of prescriptions; acute hepatitis/severe ALT elevation ~25%; pre‑exam rapid normalization (off‑label) ~15%; antiviral adjunct, MASH exploration, etc. ~10%. Incremental demand comes from: (1) >200 million NAFLD patients in China, driving need for anti‑inflammatory enzyme reducers; (2) increased penetration of high‑end IV formulations in liver failure and severe hepatitis; (3) volume growth of low‑cost generics after volume‑based procurement; (4) exports to Southeast Asia, Middle East. Upstream‑downstream structure: upstream – licorice cultivation and rough processing (Xinjiang, Gansu, Ningxia) and extraction/purification (Fanzhi, Tianshan, MAFCO, Norevo); midstream – formulation manufacturers (Chia Tai Tianqing, Minophagen, Kaiyin, Lepu); downstream – hospital pharmacies, retail drugstores, e‑commerce platforms. Licorice resource sustainability is a key ESG issue: over‑harvesting of wild licorice in China has been replaced by cultivated bases (e.g., Xinjiang Longhuiyuan’s 6,500 mu, Fanzhi’s own farms), but the long growth cycle (3-5 years) creates supply‑demand tension affecting raw material prices. Landscape: domestic market dominated by “Chia Tai Tianqing + Minophagen” duopoly, with generics following. Chia Tai Tianqing dominates diammonium glycyrrhizinate and magnesium isoglycyrrhizinate (Tianqing Ganmei single‑product sales ~RMB 2.7 billion in 2023); Minophagen’s originator Stronger Neo-Minophagen C maintains stable share in premium hospital segment; Fanzhi Pharmaceutical is the world’s largest licorice extract export base (No.1 in monoammonium glycyrrhizinate capacity), controlling upstream supply. Overseas, MAFCO Worldwide (US) and Norevo (Germany) are major licorice extract suppliers. Uncertainties include: (1) volume‑based procurement pressure on pricing, with some generics already included in local tenders and originators facing price cuts; (2) licorice raw material price volatility due to climate, planting area, and environmental policies; (3) generic entry after magnesium isoglycyrrhizinate patent expiry, threatening Chia Tai Tianqing’s exclusivity; (4) changes in employment medical exam standards affecting off‑label pre‑exam demand. Conclusion: Glycyrrhizic acid preparations represent a technically mature, clinically validated, structurally stable sub‑segment in hepatoprotective drugs. Core drivers are rising NAFLD/NASH prevalence and the rigid demand for safe, low‑rebound enzyme‑lowering drugs in the large chronic liver disease population. Structural features are upstream ESG‑sensitive licorice supply, midstream originator‑generic tiering, and downstream full‑spectrum coverage from acute severe to chronic management. Companies with vertically integrated API‑to‑formulation capabilities and originator innovative products (Chia Tai Tianqing, Fanzhi Pharmaceutical) will maintain stronger pricing power and profit margins under the volume‑based procurement environment.
This report is a detailed and comprehensive analysis for global Glycyrrhizic Acid Preparation market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Glycyrrhizic Acid Preparation market size and forecasts, in consumption value ($ Million), sales quantity (kg), and average selling prices (US$/kg), 2021-2032
Global Glycyrrhizic Acid Preparation market size and forecasts by region and country, in consumption value ($ Million), sales quantity (kg), and average selling prices (US$/kg), 2021-2032
Global Glycyrrhizic Acid Preparation market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (kg), and average selling prices (US$/kg), 2021-2032
Global Glycyrrhizic Acid Preparation market shares of main players, shipments in revenue ($ Million), sales quantity (kg), and ASP (US$/kg), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Glycyrrhizic Acid Preparation
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Glycyrrhizic Acid Preparation market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Minophagen Pharmaceutical, Chia Tai Tianqing Pharmaceutical, Sinoma Energy Conservation, Fanzhi Pharmaceutical, Xinjiang Tianshan Pharmaceutical, Xinjiang Longhuiyuan Pharmaceutical, Shaanxi Fujie Pharmaceutical, Alps Pharmaceutical, MAFCO Worldwide, Norevo GmbH, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Glycyrrhizic Acid Preparation market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Compound Glycyrrhizic Acid (Stronger Neo-Minophagen C)
Diammonium Glycyrrhizinate
Magnesium Isoglycyrrhizinate
Monoammonium Glycyrrhizinate & Others
Market segment by Administration
Intravenous (Rapid Onset, 1-2 weeks)
Oral (Moderate Onset, 2-4 weeks)
Market segment by Application
Acute Hepatitis & Severe ALT Elevation
Chronic Hepatitis Maintenance
Pre-Exam Rapid Normalization (Off-Label)
Adjunct to Antiviral Therapy
MASH/NASH Treatment
Others
Major players covered
Minophagen Pharmaceutical
Chia Tai Tianqing Pharmaceutical
Sinoma Energy Conservation
Fanzhi Pharmaceutical
Xinjiang Tianshan Pharmaceutical
Xinjiang Longhuiyuan Pharmaceutical
Shaanxi Fujie Pharmaceutical
Alps Pharmaceutical
MAFCO Worldwide
Norevo GmbH
Maruzen Pharmaceuticals
Qingdao Taitong Pharmaceutical
Jiangsu Tiansheng Pharmaceutical
Beijing Kaiyin Technology
Lepu Pharmaceutical
Yuandong Biopharmaceutical
Huasen Pharmaceutical
Hunan Mingrui Pharmaceutical
Xinjiang Tefeng Pharmaceutical
Shijiazhuang CSPC Ouyi Pharmaceutical
Weifang Zhongshi Pharmaceutical
Harbin Sanlian Pharmaceutical
Ruiyang Pharmaceutical
Honghe Pharmaceutical
Hubei Wushi Pharmaceutical
Anhui Shuanghe Pharmaceutical
Anhui Jinhe Industrial
Jiayuan Fragrances
Daewoong Chemical
Mitsubishi Tanabe Pharma
ICE Group
PharmaZell
Dipharma Francis
Tsumura
Kracie
Tochimoto
Itoh Kampo
Kokando
Ohmine
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Glycyrrhizic Acid Preparation product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Glycyrrhizic Acid Preparation, with price, sales quantity, revenue, and global market share of Glycyrrhizic Acid Preparation from 2021 to 2026.
Chapter 3, the Glycyrrhizic Acid Preparation competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Glycyrrhizic Acid Preparation breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Glycyrrhizic Acid Preparation market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Glycyrrhizic Acid Preparation.
Chapter 14 and 15, to describe Glycyrrhizic Acid Preparation sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Glycyrrhizic Acid Preparation. Industry analysis & Market Report on Glycyrrhizic Acid Preparation is a syndicated market report, published as Global Glycyrrhizic Acid Preparation Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Glycyrrhizic Acid Preparation market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.